Comment on: 'Metagenome-wide association study of gut microbiome revealed novel aetiology of rheumatoid arthritis in the Japanese population' by Kishikawa et al

The recent paper from Kishikawa et al1 provides an extremely important new insight on the concept of oral-gut microbiome axis and rheumatoid arthritis (RA) pathogenesis.

Alterations in the gut microbiome at mucosal sites have been implicated in the pathogenesis of RA.2-4 Increasing evidence suggests a link between RA and periodontal infections caused by Porphyromonas gingivalis (Pg).5 Oral infection by Pg in an animal model revealed increased serum levels of lipopolysaccharide (LPS), dysbiosis and aggravation of arthritis.6,7 Therefore, the pathogenesis of RA is considered to be associated with the immunomodulatory activity of oral and gut microbiome.8 However, few studies have explored the relationship between the oral-gut microbiome axis and RA pathogenesis.

We previously investigated the relationship between RA disease activity using activity indices and biomarkers; the total bacterial counts and the counts of five well-known gut bacteria species; LPS-related biomarkers and IgG and IgA anti-Pg-LPS antibodies in 87 patients with established RA showing inadequate responses to conventional synthetic disease-modifying antirheumatic drugs or exhibiting severe complications.9 (online supplementary table 1)

Little significant relationship was observed between the counts of the total bacteria, five species of bacteria and activity indices and biomarkers.1 The levels of LPS-related biomarkers, particularly serum LPS-binding protein (LBP), were positively correlated with activity indices and biomarkers, suggesting that bacterial LPS-LBP complexes from the gut microbiome may activate nuclear factor κB via toll-like receptor 4 and may initiate and perpetuate inflammation10 11 in established RA.

IgA antibody responses against Pg-LPS, were inversely correlated with the counts of intestinal bacteria, affecting the microbiome balance, and showed a positive correlation with serum LPS and LBP levels, suggesting barrier damage due to intestinal infection with Pg. These results support previous findings in collagen-induced arthritis models showing that oral administration of Pg significantly affected the gut barrier function and the gut microbiota composition, specifically by decreasing the proportion of phylum Bacteroidetes, increasing the proportion of phylum Firmicutes.7

Furthermore, IgG anti-Pg-LPS antibody levels, which are indicative of systemic infection, are inversely correlated with RA activity indices; these results are comparable to those of our previous study of destructive RA.12 Thus, these results demonstrate that the oral-gut microbiome axis relationship may aggravate disease activity in RA.

Kishikawa et al recently performed a genome-wide association study to analyse the role of the gut microbiome in RA; they compared 82 Japanese patients with early RA with 42 age-matched and sex-matched normal controls1 (online supplementary table 1).

In this study, faecal samples were subjected to whole-genome shotgun sequencing. Case-control phylogenetic association analyses, conducted using a generalised linear regression model, showed that multiple species belonging to the Prevotella genus increased in the RA gut metagenome. Multiple Prevotella spp., in addition to Prevotella copri, which was recently identified by shotgun sequencing, have been identified in the oral cavity. It has been speculated that colonisation of the intestine by oral bacteria is related to the pathogenesis of RA and other diseases suggesting existence of oral-gut microbiome axis relationship.

In Kishikawa’s study, a representative finding was decreased expression of the redox reaction-related gene R6FCZ7 which is involved in oxidative stress in the genus Bacteroides in RA than in healthy subjects. It was previously reported that the counts of Prevotella and Bacteroides in the gut in RA show an inverse relationship. They suggested that R6FCZ7 and the genus Prevotella are inversely associated via the relationship with the genus Bacteroides. In our study, levels of serum LPS, a potent generator of reactive oxygen species,12 16 as well as IgA anti-Pg-LPS antibody levels, which indicate gut infection with Pg, are inversely associated with Bacteroides counts. Both studies showed that the key gene R6FCZ7 and LPS are associated with the generation of reactive oxygen species and are regulated by the balance of gut bacteria, including oral bacteria.

From the viewpoint of clinical application, we have questions to authors after comparison with two studies discussing two oral origin microbiome; Prevotella spp. and Pg.

Prevotella copri was most abundant in patients with new-onset RA3 4 suggesting its pathogenic role. Moreover, Maeda et al reported SKG mice harbouring microbiota dominated by P. copri from early RA patients had an increased number of intestinal Th17 cells and developed destructive arthritis when treated with zymosan.4 Another microbiome from oral cavity, Pg is also considered to play a pathogenic role in RA since Pg peptidylarginine deiminase is implicated in the autoimmunity of RA by creating mimic antigen, circular citrullinated peptide (CCP), by autocitrulnination.5 Interestingly, anti-Pg-LPS antibody associated with RA clinical indices and biomarker in our study with established RA, suggesting the role for continuation of RA inflammation.6 These data by Maeda and ours might show the possibility that multiple Prevotella spp. other than P. copri or Pg play not only pathogenic but prognostic role. Were there significant differences of values in prognostic factors (rheumatoid factor, anti-CCP antibody, matrix metalloproteinase 3, HLA-DRBI gene, bone erosion and so on) between high and low abundant groups in multiple Prevotella spp. or Pg? ; results from such analyses would have provided crucial information for understanding of RA pathogenesis.

Overall, our findings and those of others suggest that modulation of the oral-gut microbiome axis is a promising strategy for the treatment and management of RA.
Correspondence

Table 1  Relationships between RA activity indices, disease biomarkers, gut bacterial counts, LPS-related biomarkers and IgG and IgA anti-Pg LPS antibodies in 87 patients with RA.

<table>
<thead>
<tr>
<th>Activity indices</th>
<th>Disease biomarker</th>
<th>LPS-related biomarker</th>
<th>Anti-Pg LPS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Top: disease values from bootstrap p value</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DA28-ESR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DK28-ESR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SJC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TJC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pVAS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>dVAS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pain VAS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hand VAS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SDAI</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CDAI</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ESR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CRP</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IF</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-CCP</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hb</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MMP-3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TNF</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-6</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Bacterial DNA extracted from individual faecal samples was subjected to real time-parametric rank correlation analysis.

The methods used are as follows: LPS-related biomarkers and IgG and IgA anti-Pg LPS antibodies, as described in references.† The Anti-Pg LPS assay is a disease activity index in RA. The disease biomarkers ESR, CCP, Hb, and MMP-3 were determined as described in references. The LTA system was used to determine anti-Pg LPS antibodies. The anti-Pg LPS IgG and IgA antibodies were measured using the LPS-Associated Questionnaire.
Kaori Kitamura,1 Hiroshi Shionoya,1 Kuniaki Terato,2 Suguru Suzuki,1 Richio Fukai,1 Shinichi Uda,1 Chiyuki Abe,3 Hiromitsu Takeomori,6 Keita Nishimura,7 Takashi Watanuki8 Kou Katayama9
1Research Lab Section 5, Asama Chemical Co Ltd, Tokyo, Japan
2Research and Development, Chondrex, Inc, Redmond, Washington, USA
3Pharmacology, Fukai Pharmacy, Asahikawa, Hokkaido, Japan
4Rheumatology, Uda Clinic of Rheumatology, Fukuyama, Hiroshima, Japan
5Rheumatology, Abe Clinic Internal Medicine, Tokyo, Japan
6Rheumatology, Aomori Prefectural Central Hospital, Aomori, Aomori, Japan
7Rheumatology, Teikyo University School of Medicine, Tokyo, Japan
8Company Rheumatology, Katayama Orthopedic Rheumatology Clinic, Asahikawa, Hokkaido, Japan
9Rheumatology, Katayama Orthopedic Rheumatology Clinic, Asahikawa, Hokkaido, Japan

Correspondence to Dr Kou Katayama, Rheumatology, Katayama Orthopedic Rheumatology Clinic, Asahikawa, Hokkaido 078-8243, Japan; kou@kata-rheum.or.jp

Acknowledgements The authors thank our colleagues Jessica Chang and Bonnie McKinney for reviewing and proofreading this manuscript. The authors thank Kiyomi Kamiya for assistance for patients’ data collection.

Contributors HS, KoK and KT designed basic study plans, acquired, analysed and interpreted the data. KoK, KaK, HS, HB and KT drafted this manuscript. KaK, SS conducted most of the analysis in this study including faecal bacteria and LPS-related biomarker analysis. KoK, SU, CA, HT and KN conducted the clinical study with their patients. TW confirmed data by conducting related, but independent experiments, interpreted data and contributed to the preparation of this manuscript. RF conducted the statistical analysis and interpreted the data based on statistical significance. All authors have read and approved of the final manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; internally peer reviewed. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.


Received 1 May 2020
Revised 6 May 2020
Accepted 6 May 2020

References